Skip to main content

Table 1 Baseline characters of the 9,184,146 vaccine recipients on December 27, 2020 and vaccination status on November 30, 2021

From: Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy

Baseline characteristics

 

Sex

 

 Men

4,715,243 (51.3%)

 Women

4,468,903 (48.7%)

Age categories

 

 12–15 years

401,186 (4.4%)

 16–19 years

387,685 (4.2%)

 20–29 years

977,758 (10.7%)

 30–39 years

1,130,699 (12.3%)

 40–49 years

1,493,328 (16.3%)

 50–59 years

1,665,591 (18.1%)

 60–69 years

1,254,101 (13.7%)

 70–79 years

1,026,382 (11.2%)

 80 + years

847,416 (9.2%)

Cardiac comorbidities

 

 Arrhythmic myocardiopathy

237,941 (2.6%)

 Arterial vascular disease

76,321 (0.8%)

 Familial and non-familial hypercholesterolaemia

274,477 (3.0%)

 Heart failure

161,551 (1.8%)

 Hypertension

1,285,967 (14.0%)

 Ischaemic heart disease

246,631 (2.7%)

 Non-arrhythmic myocardiopathy

245,683 (2.7%)

 Valvular heart disease

69,656 (0.8%)

 Venous vascular disease

41,184 (0.5%)

 At least one cardiac comorbidity

2,255,136 (24.5%)

Vaccine status

 First dose

7,907,765 (86.1%)

  Oxford-AstraZeneca

1,223,681 (13.3%)

  Janssen

289,989 (3.2%)

  Moderna

1,024,935 (11.2%)

  Pfizer-BioNTech

5,369,160 (58.5%)

 Second dose

7,165,379 (78.0%)

  Oxford-AstraZeneca

1,041,884 (11.3%)

  Moderna

970,629 (10.6%)

  Pfizer-BioNTech

5,152,866 (56.1%)

 Third dose (booster)

1,052,469 (11.5%)

  Moderna

108,319 (1.2%)

  Pfizer-BioNTech

944,150 (10.3%)